Head of Cardiovascular Surgery Department Altınbaş University, Faculty of Medicine, Turkey.
J Wound Care. 2023 Apr 1;32(Sup4):S14-S21. doi: 10.12968/jowc.2023.32.Sup4.S14.
Diabetic foot ulcers (DFUs) cause high morbidity and mortality despite best treatment. Thus, new products are urgently needed to treat DFUs. Intralesional epidermal growth factor (EGF) (Heberprot-p) is considered to be an adjuvant therapy to standard of care (SOC) in DFUs. In the present study, the effect of Heberprot-p treatment on wound healing is compared to standard treatment.
The data of patients with DFUs were retrospectively analysed. The patients who had had DFUs of at least four weeks' duration and who had been treated in the wound clinic between January 2014 and 2017 were included in the study. The patients were divided into study and control groups. The study group consisted of patients in whom intralesional recombinant human EGF, Heberprot-p 75μg, was applied; the control group consisted of the remaining patients in whom EGF was not applied. The efficacy of Heberprot-p treatment in Wagner 2 and 3 DFUs were retrospectively investigated.
The study group (n=29 patients) who received Heberprot-p treatment was found to have shorter treatment times and higher rates of wound healing than the control group (n=22 patients). Although the amputation rate in the study group was less than the control group, the difference was not statistically significant.
Heberprot-p therapy is a promising treatment in DFUs, which can be routinely used as an adjunct to standard care.
尽管采用了最佳治疗方法，糖尿病足溃疡（DFU）仍会导致高发病率和死亡率。因此，迫切需要新的产品来治疗 DFU。真皮内表皮生长因子（EGF）（Heberprot-p）被认为是 DFU 标准治疗（SOC）的辅助治疗。在本研究中，将 Heberprot-p 治疗对伤口愈合的影响与标准治疗进行了比较。
回顾性分析了 DFU 患者的数据。纳入研究的患者为患有至少四周持续时间的 DFU 且于 2014 年 1 月至 2017 年期间在伤口门诊接受治疗的患者。患者被分为研究组和对照组。研究组包括接受真皮内重组人 EGF（Heberprot-p 75μg）治疗的患者；对照组包括未接受 EGF 治疗的患者。回顾性调查了 Heberprot-p 治疗 Wagner 2 和 3 期 DFU 的疗效。
与对照组（n=22 例）相比，接受 Heberprot-p 治疗的研究组（n=29 例）的治疗时间更短，伤口愈合率更高。尽管研究组的截肢率低于对照组，但差异无统计学意义。
Heberprot-p 治疗是 DFU 的一种有前途的治疗方法，可以常规用作标准治疗的辅助治疗。
